Introduction : We investigated the clinical significance of the peritoneal clearance of levofloxacin, which is used to treat exit-site infections caused by Pseudomonas aeruginosa in patients under continuous ambulatory peritoneal dialysis (CAPD) , and proposed an optimum dose and dosage interval for treating these patients.
Methods : We measured the concentrations of levofloxacin in the plasma , the drainage from peritoneal dialysis and the plasma ultrafiltrate by HPLC in 6 patients receiving CAPD, and determined the plasma unbound fraction (fuB) . We also estimated the total clearance (CLtot/F), distribution volume (Vd/F) and peritoneal clearance (CLpd) in each patient.
Results : The mean (S. D.) CLtot/F, Vd/F, CLpd, and fuB were 22 .6 (7.34) ml/min, 76.3 (21.9) L, 3.42 (0.831) ml/min, and 69.7 (13.76) %, respectively. We examined the possible factors affecting the peritoneal clearance of levofloxacin, but did not find any definite trends.
Discussion : The average CLpd was about 17% of the CLtot , but in some patients it was above 20%. It seems that the peritoneal clearance values should not be ignored in clinical practice. The minimum plasma concentration of levofloxacin in the steady state In these equations, the t1, t2, and t3 represent the time interval between the time of adminis tration of each of the doses and the time at which the plasma sample (Cptl) was collected, t4 denotes the time between the time when the patient took the drug last and the time when dosage interval of 24 h from the second day on.
The Vd/F and the elimination rate constant (kel) were calculated from the plasma concen trations measured at t1, t2, t3, and t4 using equations 1 and 2.
The CLtot/F was calculated by equation 3.
CL tot/F Equation 3
Since all patients carried out the peritoneal dialysis all day, CLpd/F of all patients involved the peritoneal clearance.
The maximum plasma concentration (Cp0) was calculated from the obtained Vd/F and CLtot/F. The area under the plasma concentra tion time curve (AUC) during the peritoneal dialysis was calculated as follows : Equation 4 Where T1 and T2 denote the start and comple tion of the dialysis, respectively, and Cp0 is the maximum plasma concentration of the day when the dialysate was collected which is esti mated from Vd/F and CLtot/F of each patient.
The CLpd was calculated from the following equation : Equation 5 Where Vpd is from the volume of peritoneal drainage dialyzed between T1 and T2 and Cpd denotes the total drug concentration in the drainage.
The plasma unbound fraction (fuB) was determined as follows :
in which Cp and Cu represent the drug concen tration in plasma and in the ultrafiltrate, respectively. (Fig. 1 ).
5) Statistical

Discussion
The CLpd is determined using a limited volume of Vpd, and is also determined under the condition that the drug level in the plasma and in the dialysate do not attain a state of equilibrium. Therefore, CLpd is presumed to change accord ing to the volume of drainage and the depot time. We examined the possible relationships and it appeared that an effective plasma con centration was maintained in many patients.
Eventually, all patients but one (No. 2) were treated successfully within the study period.
The one exception patient (No.2) refused levofloxacin after the first day of this study and thus he was excluded from the study.
However, if levofloxacin is administered at a dose of 100 mg at intervals of 48 h, the plasma concentration would likely be under the MIC50 for a significant period (Fig.2) . Based on the estimated blood concentrations, this result sug gests that with a 48 h regimen it is not possible to keep the plasma concentration high enough to obtain an appropriate antibacterial effect. In the case of other drugs, Taber et al reported that ciprofloxacin at 500 mg/day, which was one-half of the typical dose for patients with normal renal function, showed a plasma concen tration sufficient for the treatment of exit-site infection caused by P. aeruginosa in CAPD patients14). This dosage reduction (one-half) of ciprofloxacin is comparable to that of levoflox acin (one-third) in our study, suggesting that levofloxacin at 100 mg/day is preferable to the conventional dose of 100 mg/2 days since the physiochemical and pharmacokinetic profiles of ciprofloxacin are similar to those of levo floxacin.
In conclusion, CLpd accounts for an average levofloxacin. In patients whose CLpd accounts for 20% or more of the total body clearance, it would be wise to design the administration schedule of levofloxacin based on the rate of removal of the drug by CAPD. We examined the factors that may affect the CLpd of levo floxacin, but we found no definite trends, possibly because the number of patients evaluated was too small and the variation in the range of factors examined was also small.
Further studies on larger numbers of patients are necessary. However, the values for the pharmacokinetic parameters and peritoneal dialysis clearance obtained in our study suggest that levofloxacin should be administered at a dose of 300 mg a day on the first day, and then at a dose of 100 mg at intervals of 24h.
